Please wait a minute...
J Zhejiang Univ (Med Sci)  2020, Vol. 49 Issue (2): 185-190    DOI: 10.3785/j.issn.1008-9292.2020.03.09
    
Diagnostic efficacy of three test kits for SARS-CoV-2 nucleic acid detection
SHEN Lihua1(),HUANG Fei2(),CHEN Xiang1,XIONG Zuan3,YANG Xiaoyu2,LI Hui2,CHENG Feng2,GUO Jian1,*(),GONG Guofu2,*()
1. Department of Clinical Laboratory, Ezhou Maternal and Child Health Hospital, Ezhou 436000, Hubei Province, China
2. Department of Clinical Laboratory, Ezhou Central Hospital, Ezhou 436000, Hubei Province, China
3. Department of Clinical Laboratory, Egang Hospital, Ezhou 436000, Hubei Province, China
Download: HTML( 23 )   PDF(1055KB)
Export: BibTeX | EndNote (RIS)      

Abstract  

Objective: To compare the diagnostic efficacy among three RT-PCR test kits for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid detection. Methods: The throat swab samples from 40 hospitalized patients clinically diagnosed as coronavirus disease 2019 (COVID-19) and 16 hospitalized non-COVID-19 patients were recruited. The SARS-CoV-2 nucleic acid was detected in throat swab samples with RT-PCR test kits from Sansure Biotech ("Sansure" for short), Jiangsu Bioperfectus Technologies ("Bioperfectus" for short) and BGI Genomics ("BGI" for short). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and Kappa value were analyzed. The viral nucleic acid was extracted from the throat swab samples by one-step cleavage and magnetic bead methods, and the efficacy of two extraction methods was also compared. The results of magnetic bead method for nucleic acid extraction by two different extractors (Sansure Natch CS S12C Fully Automated Nucleic Acid Extraction System vs. Tianlong NP968-C Nucleic Acid Extractor) were also compared. Results: The sensitivity, specificity, PPV, NPV and kappa value were 95.00%, 87.50%, 95.00%, 87.50%and 0.825 for Sansure kit; 90.00%, 87.50%, 94.74%, 77.78%and 0.747 for the Bioperfectus kit, and 82.50%, 81.25%, 91.67%, 65.00%and 0.593 for the BGI kit, respectively. The positive, negative and total coincident rates and kappa value of viral nucleic acid detection results using the samples extracted by one-step cleavage and magnetic bead methods were 95.24%, 100.00%, 96.43%and 0.909, respectively, but the one-step cleavage method took only 25 min, while the magnetic bead method required 180 min. The positive, negative and total coincident rates and kappa value of viral nucleic acid detection results using the samples extracted by the two different nucleic acid extractors were 85.00%, 100.00%, 89.29% and 0.764, respectively. Conclusion: The detection efficacy for SARS-CoV-2 nucleic acid by the Sansure kit is relatively higher and the one-step cleavage method has advantages of convenient operation and less time consuming.



Key wordsCoronavirus disease 2019      Severe acute respiratory syndrome coronavirus 2      Novel coronavirus pneumonia      Diagnostic techniques      Polymerase chain reaction      Diagnostic efficacy     
Received: 05 March 2020      Published: 17 March 2020
CLC:  R446  
Corresponding Authors: GUO Jian,GONG Guofu     E-mail: 4458629@qq.com;416672475@qq.com;252895179@qq.com;402389961@qq.com
Cite this article:

SHEN Lihua,HUANG Fei,CHEN Xiang,XIONG Zuan,YANG Xiaoyu,LI Hui,CHENG Feng,GUO Jian,GONG Guofu. Diagnostic efficacy of three test kits for SARS-CoV-2 nucleic acid detection. J Zhejiang Univ (Med Sci), 2020, 49(2): 185-190.

URL:

http://www.zjujournals.com/med/10.3785/j.issn.1008-9292.2020.03.09     OR     http://www.zjujournals.com/med/Y2020/V49/I2/185


严重急性呼吸综合征冠状病毒2(SARS-CoV-2)核酸检测试剂盒临床诊断效能评估

目的: 了解三种严重急性呼吸综合征冠状病毒2(SARS-CoV-2)核酸检测试剂盒的检测效果及临床诊断效能。方法: 采集40例临床诊断为2019冠状病毒病(COVID-19)和16例非COVID-19住院患者的咽拭子样本。采用湖南圣湘生物科技有限公司(以下简称“圣湘公司”)、硕世生物科技股份有限公司(以下简称“硕世公司”)、深圳华大基因股份有限公司(以下简称“华大基因”)SARS-CoV-2核酸RT-PCR检测试剂盒检测上述样本并分析其敏感度、特异度、阳性预测值、阴性预测值和Kappa值。比较一步裂解法和磁珠法、两种不同核酸提取仪(圣湘公司Natch CS S12C全自动核酸提取系统和西安天隆科技有限公司NP968-C核酸提取仪)磁珠法提取咽拭子样本中病毒核酸的效果及其RT-PCR检测结果的阳性符合率、阴性符合率、总符合率及Kappa值。结果: 圣湘公司试剂盒检测SARS-CoV-2核酸的敏感度、特异度、阳性预测值、阴性预测值和Kappa值分别为95.00%、87.50%、95.00%、87.50%和0.825,硕世公司试剂盒分别为90.00%、87.50%、94.74%、77.78%和0.747,华大基因试剂盒分别为82.50%、81.25%、91.67%、65.00%和0.593。一步裂解法和磁珠法提取的病毒核酸检测结果阳性符合率、阴性符合率、总符合率和Kappa值分别为95.24%、100.00%、96.43%、0.909,但一步裂解法仅耗时25 min,而磁珠法需180 min。两种不同核酸提取仪磁珠法提取的RNA检测结果阳性符合率、阴性符合率、总符合率和Kappa值分别为85.00%、100.00%、89.29%和0.764。结论: 圣湘公司试剂盒检测SARS-CoV-2核酸效果略优于其他两家公司试剂盒。一步裂解法提取咽拭子样本中总RNA具有操作简单、省时和检测结果符合率较高的优点。


关键词: 2019冠状病毒病,  严重急性呼吸综合征冠状病毒2,  新型冠状病毒肺炎,  诊断技术,  聚合酶链反应,  诊断效能 
试剂盒 靶基因 核酸提取 加样量
(μL)
扩增温度和循环数结果判断最低检测限
(拷贝数/mL)
内标
阳性 阴性
  SARS-CoV-2:严重急性呼吸综合征冠状病毒2;Ct值:每个反应管内的荧光信号到达设定阈值时所经历的循环数.
圣湘公司 ORF1ab/N 磁珠法
一步裂解法
10
20
60 ℃ 45个循环 S型扩增曲线
Ct值≤40
Ct值>40 200
硕世公司 ORF1ab/N 磁珠法 5 55 ℃ 45个循环 S型扩增曲线
Ct值≤35
Ct值>38 1000
华大基因 ORF1ab 磁珠法 10 60 ℃ 40个循环 S型扩增曲线
Ct值≤38
不呈S型曲线
且无Ct值
100
Tab 1 Basic information and technique index of three test kits for SARS-CoV-2 nucleic acid detection
试剂盒COVID-19样本(n=40)非COVID-19样本(n=16)
阳 性 阴 性 阳 性 阴 性
  SARS-CoV-2:严重急性呼吸综合征冠状病毒2;COVID-19:2019冠状病毒病.
圣湘公司 38 2 2 14
硕世公司 36 4 2 14
华大基因 33 7 3 13
Tab 2 Diagnosis efficacy of three test kits for SARS-CoV-2 nucleic acid detection
总RNA
提取方法
COVID-19样本(n=40)非COVID-19样本(n=16)
阳 性 阴 性 阳 性 阴 性
  COVID-19:2019冠状病毒病.
一步裂解法 40 0 2 14
磁珠法 38 2 2 14
Tab 3 Results of one-step cleavage and magnetic bead methods
核酸
提取仪
COVID-19样本(n=40)非COVID-19样本(n=16)
阳 性 阴 性 阳 性 阴 性
  COVID-19:2019冠状病毒病.
圣湘公司 38 2 2 14
天隆公司 33 7 1 15
Tab 4 The influence of different nucleic acid extractors on the detection
[1]   SU S , WONG G , SHI W et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses[J]. Trends Microbiol, 2016, 24 (6): 490- 502
doi: 10.1016/j.tim.2016.03.003
[2]   BANERJEE A , KULCSAR K , MISRA V et al. Bats and coronaviruses[J]. Viruses, 2019, 11 41- 55
doi: 10.3390/v11010041
[3]   WU F , ZHAO S , YU B et al. A new coronavirus associated with human respiratory disease in China[J]. Nature, 2020, 579 (7798): 265- 269
doi: 10.1038/s41586-020-2008-3
[4]   赵文明, 宋述慧, 陈梅丽 et al. 2019新型冠状病毒信息库[J]. 遗传, 2020, 42 (2): 212- 221
ZHAO Wenming , SONG Shuhui , CHEN Meili et al. The 2019 novel coronavirus resource[J]. Hereditas (Beijing), 2020, 42 (2): 212- 221
doi: 10.16288/j.yczz.20-030
[5]   ZHANG W , DU R H , LI B et al. Molecular and serological investigation of 2019-nCoV infected patients:implication of multiple shedding routes[J]. Emerg Microbes Infect, 2020, 9 (1): 386- 389
doi: 10.1080/22221751.2020.1729071
[6]   中华人民共和国国家卫生健康委员会办公厅, 国家中医药管理局办公室.新型冠状病毒感染的肺炎诊疗方案(试行第六版)[A/OL].国卫办医涵[2020] 145号.(2020-02-18)[2020-02-28].http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml.
General Office of National Health Commission of the People's Republic of China, Office of National Administration of Traditional Chinese Medicine. Diagnosis and treatment of novel coronavirus pneumonia (trial version 6)[A/OL]. No.145[2020] of the General Office of the National Health Commission. (2020-02-18)[2020-02-28]. http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml. (in Chinese)
[7]   CORMAN V M , LANDT O , KAISER M et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR[J]. Euro Surveill, 2020, 25 (3):
doi: 10.2807/1560-7917.ES.2020.25.3.2000045
[8]   JIN Y H , CAI L , CHENG Z S et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)[J]. Mil Med Res, 2020, 7 (1): 4
doi: 10.1186/s40779-020-0233-6
[9]   钟慧钰, 赵珍珍, 宋兴勃 et al. 新型冠状病毒核酸临床检测要点及经验[J]. 国际检验医学杂志, 2020, 41 (5): 523- 526
ZHONG Huiyu , ZHAO Zhenzhen , SONG Xingbo et al. Clinical points and experience in nucleic acid testing of SARS-CoV-2[J]. International Journal of Laboratory Medicine, 2020, 41 (5): 523- 526
doi: 10.3969/j.issn.1673-4130.2020.05.003
[10]   医疗机构临床基因扩增检验实验室管理办法[A].卫办医政发[2010] 194号, 2010.
Administration of gene amplification in medical institutions[A]. No.194[2010] of the General Office of the National Health Commission, 2010. (in Chinese)
[11]   中华人民共和国卫生健康委员会.新型冠状病毒实验室生物安全指南(第二版)[A/OL].国卫办科教函[2020] 70号.(2020-01-23)[2020-02-28].http://www.nhc.gov.cn/xcs/zhengcwj/202001/0909555408d842a58828611dde2e6a26.shtml.
National Health Commission of the People's Republic of China. Laboratory biosafety guide of 2019 novel coronavirus (version 2)[A/OL]. No.70[2020] of the General Office of the National Health Commission. (2020-01-23)[2020-02-28]. http://www.nhc.gov.cn/xcs/zhengcwj/202001/0909555408d842a58828611dde2e6a26.shtml. (in Chinese)
[12]   中华人民共和国卫生健康委员会.新型冠状病毒感染的肺炎实验室检测技术指南(第四版)[A/OL].国卫办疾控函[2020] 109号.(2020-02-07)[2020-03-10].http://www.nhc.gov.cn/jkj/s3577/202002/573340613ab243b3a7f61df260551dd4.shtml.
National Health Commission of the People's Republic of China. Technical guidelines for laboratory detection of novel coronavirus pneumonia (version 4)[A/OL]. No.109[2020] of the General Office of the National Health Commission. (2020-02-07)[2020-03-10].http://www.nhc.gov.cn/jkj/s3577/202002/573340613ab243b3a7f61df260551dd4.shtml. (in Chinese)
[13]   施绍瑞, 聂滨, 郭渝 et al. 新型冠状病毒肺炎病例多种生物样本的病毒核酸检测结果[J]. 华西医学, 2020, 35 (2): 132- 136
SHI Shaorui , NIE Bin , GUO Yu et al. Detection of novel coronavirus nucleic acid in various biological samples from patients with novel coronavirus pneumonia[J]. West China Medical Journal, 2020, 35 (2): 132- 136
doi: 10.7507/1002-0179.202002063
[1] WANG Jincheng,LIU Jinpeng,WANG Yuanyuan,LIU Wei,CHEN Xiaoqun,SUN Chao,SHEN Xiaoyong,WANG Qidong,WU Yaping,LIANG Wenjie,RUAN Lingxiang. Dynamic changes of chest CT imaging in patients with COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 191-197.
[2] ZHANG Xiaoyan, SUN Wei, SHANG Shiqiang, MAO Jianhua, FU Junfen, SHU Qiang, JIANG Kewen. Principles and suggestions on biosafety protection of biological specimen preservation during prevalence of COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 170-177.
[3] CAO Shengli,FENG Peihua,SHI Pengpeng. Study on the epidemic development of COVID-19 in Hubei province by a modified SEIR model[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 178-184.
[4] CHEN Jun,LIU Danping,LIU Li,LIU Ping,XU Qingnian,XIA Lu,LING Yun,HUANG Dan,SONG Shuli,ZHANG Dandan,QIAN Zhiping,LI Tao,SHEN Yinzhong,LU Hongzhou. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 215-219.
[5] CHEN Zhimin,FU Junfen,SHU Qiang,WANG Wei,CHEN Yinghu,HUA Chunzhen,LI Fubang,LIN Ru,TANG Lanfang,WANG Tianlin,WANG Yingshuo,XU Weize,YANG Zihao,YE Sheng,YUAN Tianming,ZHANG Chenmei,ZHANG Yuanyuan. Diagnosis and treatment recommendation for pediatric COVID-19 (the second edition)[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 139-146.
[6] XU Kaijin,CAI Hongliu,SHEN Yihong,NI Qin,CHEN Yu,HU Shaohua,LI Jianping,WANG Huafen,YU Liang,HUANG He,QIU Yunqing,WEI Guoqing,FANG Qiang,ZHOU Jianying,SHENG Jifang,LIANG Tingbo,LI Lanjuan. Management of COVID-19: the Zhejiang experience[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 147-157.
[7] JIANG Saiping,LI Lu,RU Renping,ZHANG Chunhong,RAO Yuefeng,LIN Bin,WANG Rongrong,CHEN Na,WANG Xiaojuan,CAI Hongliu,SHENG Jifang,ZHOU Jianying,LU Xiaoyang,QIU Yunqing. Pharmaceutical care for severe and critically ill patients with COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 158-169.
[8] LI Xin,DAI Tian,WANG Hong,SHI Junnian,YUAN Wei,LI Jing,CHEN Lijun,ZHANG Tianming,ZHANG Shanshan,KONG Yan,YUE Ning,SHI Hui,HE Yuping,HU Huifang,LIU Furong,YANG Caixia. Clinical analysis of suspected COVID-19 patients with anxiety and depression[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 203-208.
[9] LUO Song,YANG Lijuan,WANG Chun,LIU Chuanmiao,LI Dianming. Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 227-231.
[10] HONG Dongsheng,NI Jian,SHAN Wenya,LI Lu,HU Xi,YANG Hongyu,ZHAO Qingwei,ZHANG Xingguo. Establishment of a rapid identification of adverse drug reaction program in R language implementation based on monitoring data[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 253-259.
[11] ZHONG Qi,LI Zhi,SHEN Xiaoyong,XU Kaijin,SHEN Yihong,FANG Qiang,CHEN Feng,LIANG Tingbo. CT imaging features of patients with different clinical types of COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 198-202.
[12] KANG Xianhui,ZHANG Rong,HE Huiliang,YAO Yongxing,ZHENG Yueying,WEN Xiaohong,ZHU Shengmei. Anesthesia management in cesarean section for patient with COVID-19: a case report[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 249-252.
[13] CHEN Xu,LI Yang,WANG Jinxi,CAI Hongliu,CAO Hongcui,SHENG Jifang. Pregnant women complicated with COVID-19: a clinical analysis of 3 cases[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 240-244.
[14] ZHAGN Sheng,LI Danping,CHEN Huazhong,ZHENG Dan,ZHOU Yiping,CHEN Baoguo,SHI Weiwu,LIN Ronghai. Dynamic inflammatory response in a critically ill COVID-19 patient treated with corticosteroids[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 220-226.
[15] LI Youjiang,HU Yingying,ZHANG Xiaodong,YU Yuanyuan,LI Bin,WU Jianguo,WU Yingping,XIA Xiaoping,XU Jian. Follow-up testing of viral nucleic acid in discharged patients with moderate type of COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 270-274.